Direct renin inhibition with aliskiren in hypertension and target organ damage.

The Joint National Committee and the World Health Organization are in agreement that hypertension in most patients who are treated is controlled inadequately and that rates of cardiovascular morbidity remain high. Additional pharmacologic treatments could ameliorate this situation. The renin-angiotensin-aldosterone system has been a highly successful pharmacologic target, as the system is strongly implicated in the development of hypertension-related target organ damage. However, compensatory increases in plasma renin levels that lead to adjustments in angiotensin production and conversion present limitations for existing renin-angiotensin-aldosterone system inhibitors. A once-daily, orally effective, small-molecule renin inhibitor, aliskiren, is now available to address angiotensin production directly at its rate-limiting step. Studies in humans attest to an effective BP-lowering effect, a side effect profile no different from AT1 receptor blockers, and the option of combination therapies. A novel animal model of high human renin hypertension in the rat attest to target organ protection. Because angiotensin receptor blockade, angiotensin-converting enzyme inhibition, calcium channel blockade, and diuretic therapy all lead to sharp increases in plasma renin activity, aliskiren offers a novel circumvention.

[1]  M. Wellner,et al.  Complement Activation in Angiotensin II–Induced Organ Damage , 2005, Circulation research.

[2]  M. Wellner,et al.  Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats , 2005, Hypertension.

[3]  A. Danser,et al.  Renin, prorenin and the putative (pro)renin receptor. , 2005, Hypertension.

[4]  K. Bernstein,et al.  Six Truisms Concerning ACE and the Renin-Angiotensin System Educed From the Genetic Analysis of Mice , 2005, Circulation research.

[5]  Hyung-Suk Kim,et al.  Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. , 2005, The Journal of clinical investigation.

[6]  N. Hollenberg,et al.  Renin inhibition: what are the therapeutic opportunities? , 2005, Journal of the American Society of Nephrology : JASN.

[7]  R. Schmieder,et al.  Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.

[8]  R. Carey,et al.  Angiotensin Subtype-2 Receptors Inhibit Renin Biosynthesis and Angiotensin II Formation , 2005, Hypertension.

[9]  Joël Ménard,et al.  Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. , 2004, Journal of the American Society of Nephrology : JASN.

[10]  H. Hauner,et al.  Angiotensin II Stimulates the Release of Interleukin-6 and Interleukin-8 From Cultured Human Adipocytes by Activation of NF-κB , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Ménard,et al.  Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists , 2004, Circulation.

[12]  M. Cooper,et al.  Retinal Expression of Vascular Endothelial Growth Factor Is Mediated by Angiotensin Type 1 and Type 2 Receptors , 2004, Hypertension.

[13]  E. Lonn,et al.  Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report , 2002, Cardiovascular Drugs and Therapy.

[14]  J. Laragh,et al.  Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. , 2004, American journal of hypertension.

[15]  H. Hauner,et al.  Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[16]  A. Stanton,et al.  Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren , 2003, Hypertension.

[17]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[18]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[19]  J. Simonsen,et al.  Effects of truncated angiotensins in humans after double blockade of the renin system. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[20]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[21]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[22]  H. Hense,et al.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. , 2003, JAMA.

[23]  J. Staessen,et al.  Essential hypertension , 2003, The Lancet.

[24]  J. Laragh,et al.  Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. , 2003, American journal of hypertension.

[25]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[26]  T. Kahan,et al.  Relationships between left ventricular mass and the renin–angiotensin system, catecholamines, insulin and leptin , 2002, Journal of internal medicine.

[27]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[28]  G. Wuerzner,et al.  Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril , 2002, Hypertension.

[29]  John E. Hall,et al.  Hypertension—Opportunities and Challenges , 2002 .

[30]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[31]  F. Chiarelli,et al.  Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes , 2001, Pediatric Nephrology.

[32]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[33]  G. Sanz,et al.  Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.

[34]  G. Fulcher,et al.  The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. , 1999, Journal of diabetes and its complications.

[35]  N. Hollenberg,et al.  Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. , 1998, Hypertension.

[36]  O. Smithies.  A Mouse View of Hypertension , 1997 .

[37]  J. Laragh,et al.  Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. , 1997, American journal of hypertension.

[38]  O. Smithies.  Theodore Cooper Memorial Lecture. A mouse view of hypertension. , 1997, Hypertension.

[39]  J. Ménard,et al.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. , 1996, The Journal of clinical investigation.

[40]  J. Laragh,et al.  Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site. , 1996, American journal of hypertension.

[41]  J. Ménard,et al.  Effects of Blocking the Angiotensin II Receptor, Converting Enzyme, and Renin Activity on the Renal Hemodynamics of Normotensive Guinea Pigs , 1993, Journal of cardiovascular pharmacology.

[42]  A. Branzi,et al.  Evidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors , 1993, Journal of clinical pharmacology.

[43]  D. Ganten,et al.  Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Munafo,et al.  Effect of the Renin Response During Renin Inhibition: Oral Ro 42–5892 in Normal Humans , 1991, Journal of cardiovascular pharmacology.

[45]  J. Wood,et al.  Renal vasodilatation after inhibition of renin or converting enzyme in marmoset. , 1986, The American journal of physiology.

[46]  G. Keeton,et al.  Elevated plasma renin activity associated with renal dysfunction. , 1986, Nephron.

[47]  D. Wilson,et al.  Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. , 1985, The New England journal of medicine.

[48]  C. Sweet,et al.  Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure. , 1984, Journal of cardiovascular pharmacology.

[49]  D. Veber,et al.  Novel renin inhibitors containing the amino acid statine , 1983, Nature.

[50]  J. Bing.  Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[51]  G GUIMARAES,et al.  Essential hypertension , 1950, Revue de medecine aeronautique.